[go: up one dir, main page]

HK1170429A1 - 用於治療認知障礙的α-氨基酰胺衍生物 - Google Patents

用於治療認知障礙的α-氨基酰胺衍生物 Download PDF

Info

Publication number
HK1170429A1
HK1170429A1 HK12111289.3A HK12111289A HK1170429A1 HK 1170429 A1 HK1170429 A1 HK 1170429A1 HK 12111289 A HK12111289 A HK 12111289A HK 1170429 A1 HK1170429 A1 HK 1170429A1
Authority
HK
Hong Kong
Prior art keywords
cognitive
disease
disorders
benzylamino
impairment
Prior art date
Application number
HK12111289.3A
Other languages
English (en)
Chinese (zh)
Other versions
HK1170429B (en
Inventor
Patricia Salvati
Stefano Rossetti
Luca Benatti
Original Assignee
Newron Pharmaceuticals, S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticals, S.P.A. filed Critical Newron Pharmaceuticals, S.P.A.
Publication of HK1170429A1 publication Critical patent/HK1170429A1/xx
Publication of HK1170429B publication Critical patent/HK1170429B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4021-aryl substituted, e.g. piretanide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
HK12111289.3A 2006-06-15 2012-11-08 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders HK1170429B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012352A EP1870097A1 (en) 2006-06-15 2006-06-15 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EP06012352.8 2006-06-15

Publications (2)

Publication Number Publication Date
HK1170429A1 true HK1170429A1 (zh) 2013-03-01
HK1170429B HK1170429B (en) 2015-11-20

Family

ID=

Also Published As

Publication number Publication date
RS54324B1 (en) 2016-02-29
EP1870097A1 (en) 2007-12-26
CN101466366A (zh) 2009-06-24
WO2007144153A2 (en) 2007-12-21
JP2013155186A (ja) 2013-08-15
TW200808696A (en) 2008-02-16
JP2009539908A (ja) 2009-11-19
HUE026484T2 (en) 2016-06-28
AU2007260239B2 (en) 2012-08-30
IL195906A0 (en) 2009-09-01
EP2029130A2 (en) 2009-03-04
CY1116699T1 (el) 2017-03-15
EP2343064A1 (en) 2011-07-13
US8741957B2 (en) 2014-06-03
AU2007260239A1 (en) 2007-12-21
EA018006B1 (ru) 2013-04-30
EP2977046A1 (en) 2016-01-27
HRP20151026T1 (hr) 2015-10-23
SI2029130T1 (sl) 2015-11-30
PT2029130E (pt) 2015-10-28
ES2549113T3 (es) 2015-10-23
JP6119068B2 (ja) 2017-04-26
AR061505A1 (es) 2008-09-03
BRPI0712994A2 (pt) 2012-03-27
US20100016437A1 (en) 2010-01-21
WO2007144153A3 (en) 2008-03-13
MX2008016017A (es) 2009-01-16
EA200802306A1 (ru) 2009-06-30
ME02343B (me) 2016-06-20
CA2655243A1 (en) 2007-12-21
PL2029130T3 (pl) 2016-01-29
CN102512406B (zh) 2015-01-07
EP2029130B1 (en) 2015-08-19
CN102512406A (zh) 2012-06-27
CA2655243C (en) 2015-06-02
IL195906A (en) 2016-02-29
TWI494293B (zh) 2015-08-01
DK2029130T3 (en) 2015-11-16
KR20090018817A (ko) 2009-02-23
NZ573565A (en) 2013-01-25

Similar Documents

Publication Publication Date Title
AU2007260239B2 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
JP2013067647A (ja) パーキンソン病を治療するための方法
JP2019517469A (ja) ピプラドロールを用いる行動症候群の治療方法
TWI831896B (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
HK1170429B (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HK1133191A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
PFEFFERBAUM et al. Narcolepsy, paranoid psychosis, and tardive dyskinesia: a pharmacological dilemma
HK1111081A (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2840314C1 (ru) Лечение боязни публичного выступления агонистом альфа-7 никотинового ацетилхолинового рецептора
JP2008502607A (ja) 痴呆の予防および治療におけるL−n−ブチルフタリドの適用
Soroka et al. Ketamine in affective disorders–expectations and limitations
Riekkinen et al. Combined nicotinic and muscarinic cholinergic and serotonergic blockade selectively impair acquisition of spatial navigation
CA3199760A1 (en) Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist
JP2003525241A (ja) 機能性胃腸疾患治療用トラマドール
Fox The pharmacological basis of Parkinson’s disease therapy: an overview
Broekhuizen et al. AC Baakman1, R. Alvarez-Jimenez1, G. Loewen², ML de Kam1
JP2012136545A (ja) 痴呆の予防および治療におけるL−n−ブチルフタリドの適用
CA2550604A1 (en) Methods for treating smooth muscle disorders using trospium